After researching with key industry players about strategies for drug repositioning, I noticed that there are numerous approaches in the fields of screening and docking-type technologies.
This week, a very interesting article was published in The Economist, about a method developed by Sivanesan Dakshanamurthy, a molecular biologist at Georgetown University in Washington, DC, potentially shortcutting the repurposing of drugs.
The technology has made several associations between drugs and targets that are novel and testable, so even if it works for just a few drugs, it would be a big advantage; especially if it is approached through multi-stakeholder collaboration.
Read the full article here.
Dr. Dakshanamurthy will be presenting this approach at US's World Drug Repositioning Congress this December in DC.